Jing Cui, PhD, Discusses Next Steps for Risk Prediction Models for SLE

Video

In this video interview, Dr. Jing Cui explains what the next steps could be for the risk prediction models of systemic lupus erythematosus.

A study presented at the American College of Rheumatology 2021 Convergence assessed risk prediction models incident systemic lupus erythematosus (SLE) using lifestyle and environmental risk factors as well as a genetic risk score.

Jing Cui, PhD, Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School said that she would like to include more diversity as well as environmental factors in future research, such as family history, air pollution, sleep, and stress.

Cui noted that this population had a majority of White and Asian females. This is something to pay attention to when evaluating the results because other research has shown disparities in racial groups when it comes to systemic lupus erythematosus risk and prevalence, especially among the Black population.

The most influential factors according to this particular study included the weighted genetic risk scores (wGRS), obesity, and a young age of menarche (less than 10 years).

However, Cui mentioned that the investigators are looking to expand on these results by collecting data from a population that is at least 50% non-white. This will help display a more well-rounded representation of the data across racial/ethnic groups.

Related Videos
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
John Kane, MD: Shifts in Antipsychotics for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.